MARKET

CING

CING

Cingulate Inc
NASDAQ
4.830
-0.110
-2.23%
After Hours: 4.848 +0.018 +0.38% 18:19 06/23 EDT
OPEN
4.860
PREV CLOSE
4.940
HIGH
5.00
LOW
4.800
VOLUME
222.74K
TURNOVER
--
52 WEEK HIGH
11.89
52 WEEK LOW
3.160
MARKET CAP
65.06M
P/E (TTM)
-1.1164
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CING last week (0615-0619)?
Weekly Report · 1d ago
Cingulate Gains Key U.S. Patent for Lead ADHD Drug
TipRanks · 06/16 12:46
Cingulate issues patent by USPTO for CTx-1301
TipRanks · 06/16 12:17
Cingulate wins first US patent for ADHD drug CTx-1301, exclusivity to December 2042
PUBT · 06/16 12:02
Weekly Report: what happened at CING last week (0608-0612)?
Weekly Report · 06/15 10:32
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 06/09 13:39
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase
TipRanks · 06/09 02:12
Cingulate director Jeff Hargroves acquires 97,276 common shares for $490,271.04
PUBT · 06/08 23:02
More
About CING
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.

Webull offers Cingulate Inc stock information, including NASDAQ: CING real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CING stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CING stock methods without spending real money on the virtual paper trading platform.